Form 4: Arcus Biosciences President Sells Shares via 10b5-1 Plan

Arcus Biosciences President Juan C. Jaen sold 31,823 shares of common stock on January 5, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Juan C. Jaen, President of Arcus Biosciences, Inc. (RCUS), reported the sale of 31,823 shares of common stock.
• The transactions occurred on January 5, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on August 8, 2025.
• The sales included 29,670 shares at a weighted average price of $21.34, with prices ranging from $20.975 to $21.84.
• An additional 2,053 shares were sold at a weighted average price of $22.34, with prices ranging from $22.04 to $22.985.
• A further 100 shares were sold at a price of $23.20.
• Following these transactions, Mr. Jaen beneficially owns 922,240 shares indirectly through a Trust and 346,012 shares directly, which includes unvested RSU grants.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a high-ranking executive selling a significant number of shares. However, the negative impact is mitigated by the fact that the sales were pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing personal holdings rather than an immediate reaction to company-specific news.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions and reducing the implication of trading on immediate inside information.
• The use of a 10b5-1 plan demonstrates adherence to SEC regulations for insider trading.

Negatives

• A high-ranking executive selling a significant number of shares (31,823 shares totaling approximately $681,296) can be perceived by the market as a potential signal of reduced confidence or a belief that the stock may be fully valued.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market interpretation of insider selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the executive's sale as a signal, potentially leading to a cautious view on the stock, despite the pre-planned nature of the transaction.

Key Dates

Recommendation

While the sale by a key executive is notable, the fact that it was executed under a pre-arranged 10b5-1 trading plan suggests a planned diversification or liquidity event rather than an immediate reaction to negative company developments. Investors should monitor future insider activity and company performance, but this single transaction, while significant in volume, does not warrant an immediate 'sell' recommendation. A 'hold' stance is appropriate, advising caution and further observation.

Keywords

Arcus Biosciences, RCUS, insider trading, Form 4, stock sale, 10b5-1 plan, executive compensation